Foundation Medicine Announces First-Ever Public Release of Broad Pediatric Data From FoundationCORE™ to Accelerate the Development of Precision Medicine Strategies for Pediatric Cancers
-Data Release Announced Today at White House Precision Medicine Initiative Summit-
"One of the biggest impediments to progress in the field of childhood cancer is the paucity of genomic data available from patients at the time of disease relapse. These data are critical to defining comprehensive strategies to precisely treat relapsed disease, and more importantly, to prevent disease recurrence in the first place," stated
FoundationCORE is a molecular information knowledgebase that contains genomic information and insights from more than 68,000 adult and pediatric patients whose tumors were profiled by
"The proposed release of data by
Pediatric cancers are a rare and diverse collection of diseases. While childhood and adolescent cancer is rare, it remains the leading cause of death by disease among children. The
"There are few things in life as devastating as when a child is diagnosed with cancer. It's critically important to the achievement of our corporate mission that the robust genomics information we have amassed is freely and easily accessible to researchers and utilized as an important tool to address the significant unmet medical need in pediatric cancers," said
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that the release of pediatric data by
1
View source version on businesswire.com: http://www.businesswire.com/news/home/20160225005087/en/
Media Contact:
973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
617-418-2215
ir@foundationmedicine.com
or
949-370-8500
matt@purecommunicationsinc.com
Source:
News Provided by Acquire Media